

1 Investigation into Reversed Phase Chromatography Peptide Separation Systems Part III:

2 Establishing a Column Characterisation Database

3 Jennifer K. Field ^a, Melvin R. Euerby ^{a,b}, Patrik Petersson ^{c*}

4 ^a *Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United*
5 *Kingdom G4 ORE*

6 ^b *Shimadzu UK, Milton Keynes, Buckinghamshire, United Kingdom MK12 5RD*

7 ^c *Novo Nordisk A/S, Måløv, Denmark DK-2760*

8 ** Author for correspondence, +45307 92146, pps@novonordisk.com*

9

10 Abstract

11 The Peptide RPC Column Characterisation Protocol was applied to 38 stationary phases, varying in
12 ligand chemistry, base silica, end capping and pore size, which are suitable for the analysis of
13 peptides. The protocol at low and intermediate pH is based on measuring retention time differences
14 between peptides of different functionality to calculate selectivity delta values. The characterisation
15 was designed to explore increases / decreases in positive or negative charge (deamidation), steric
16 effect (i.e. racemisation / switch in amino acid order), oxidation and addition / removal of aromatic
17 moieties. The necessity of developing a characterisation protocol specifically for peptide analysis was
18 highlighted by the fact that the small molecule databases (Snyder's Hydrophobic Subtraction Model
19 and the extended Tanaka protocol) failed to correlate with the Peptide RPC Column Characterisation
20 Protocol. Principal Component Analysis was used to demonstrate that the protocol could be used to
21 identify columns with similar or dissimilar chromatographic selectivity for the purpose of selectivity
22 back-up or method development columns respectively. This was validated using peptide fragments
23 derived from the tryptic digest of bovine insulin and carbonic anhydrase. It was also demonstrated
24 that the presence of positively charged functional groups on the stationary phase was advantageous
25 as it yielded very different chromatographic selectivity and improved peak shape.

26

27 Keywords

28 Database; Reversed Phase Chromatography; Characterisation; Peptides; Stationary Phase

29

30

31 **Highlights**

- 32 • 38 RPC columns were characterised at low and mid pH using a peptide based protocol
- 33 • Probes for hydrophobic, electrostatic, polar, steric and aromatic interactions
- 34 • No correlation with two protocols based on small molecules could be observed
- 35 • Prediction of similarities and differences were validated using protein digests
- 36 • Addition of positively charged functionality alters separation selectivity and improves
- 37 resolution

38

39 **1 Introduction**

40 The number of stationary phases with different ligand functionalities has increased substantially over
41 the past few decades. This greater range of chemistries has vastly increased the number of column-
42 analyte interactions with the possibility of different chromatographic selectivities available for the
43 chromatographer. However, the plethora of choice can make column selection a daunting task. The
44 selection of the stationary phase is one of the most critical parameters which affects selectivity, and
45 hence can impact on the success of developing chromatographic methods. By choosing stationary
46 phases with different chromatographic properties, the likelihood of maximising selectivity
47 differences increases, which improves the efficiency of the method development process.
48 Alternatively, selecting stationary phases which possess similar chromatographic selectivity is also an
49 important activity for the identification of a back-up column for the methodology. One effective
50 means of doing both activities is to compare column selectivity from a database where the stationary
51 phases have been characterised. Well-defined column characterisation protocols have been
52 described in the literature which utilise small molecules as probes to establish the interactions of a
53 stationary phase. Two of the largest databases are available free on the internet, which use either
54 Snyder's Hydrophobic Subtraction Model or extended Tanaka protocol by Euerby *et al.* [1-7].

55 However, the relevance of small molecule column characterisation protocols for peptides was found
56 to be minimal, with no correlation and it is believed that stationary phases should be characterised
57 using relevant probes i.e. peptide probes to assess columns used for peptide separations [8]. With
58 the recent development of the Peptide RPC Column Characterisation Protocol, it is now feasible to
59 characterise stationary phases which highlight interactions, relevant for peptide separation methods,
60 which was not feasible before [9, 10]. This protocol characterises the stationary phase at both low
61 and intermediate pH using gradient chromatography, where the solvents used were rationalised in
62 reference [9]. Twenty-six probes were designed to interrogate the phases, before being iteratively
63 assessed to reduce the number of peptides required but still adequately describe the column with

64 minimal loss of information [9]. The robustness of the protocol was critically assessed using a
65 reduced factorial design to establish which variables must be carefully controlled to ensure the
66 integrity of the protocol [10]. The definitive protocol and the mitigation necessary to ensure
67 robustness can be found elsewhere [10]. The mitigation included a further reduction of the number
68 of peptides and delta values used in the definitive protocol applied in the current study [10].

69 The newly developed peptide-based protocol was performed on 43 columns provided by six different
70 stationary phase manufacturers, the database of these results is available upon request from the
71 corresponding author. The results were collated and evaluated using principal component analysis
72 (PCA). To validate the protocol's ability to predict similarities and differences in selectivity a range of
73 stationary phases was selected from the PCA to highlight the similarity between phases for back-up
74 column purposes and phases which demonstrate selectivity differences for method development
75 strategies. Both approaches were validated using tryptic digests of carbonic anhydrase and bovine
76 insulin which produced multiple peptide fragments. The protocol was also compared against
77 characterisation approaches based on small molecules to ascertain its necessity for selecting
78 appropriate stationary phases for peptide separations. Finally, the protocol highlighted potential
79 areas for new column chemistries which could be exploited to achieve further improvements in
80 separation selectivity.

81

82 **2 Experimental**

83 *2.1 Chemicals and Reagents*

84 All water, acetonitrile and mobile phase additives (ammonium formate (AF) and formic acid (FA))
85 used were of LC-MS grade and supplied by Sigma Aldrich (Poole, UK). Dimethylsulfoxide (DMSO) was
86 supplied by Fisher Scientific (Hemel Hempstead, UK). The peptides, which were supplied by Apigenex
87 (Prague, Czech Republic), were all dissolved individually in DMSO/H₂O (80:20 v/v) to a concentration
88 of 0.25 mg/mL. Solutions were stored at -20 °C. Carbonic anhydrase, bovine insulin, trypsin, TRIS
89 base, TRIS HCl and hydrochloric acid which were used to digest the proteins to demonstrate the
90 applicability of the Peptide RPC Column Characterisation database, were supplied by Sigma Aldrich.
91 The sequences for the peptide probes followed either the base sequence for Bovine GLP-2 (1-15)
92 "HADGFSDEMNTVLD" or Bovine GLP-2 (16-33) "SLATRDFINWLIQTKITD". A further description of the
93 peptide probes can be found in references [9, 10].

94

95 *2.2 Instrumentation*

96 LC separations were performed on a Shimadzu Nexera X2 UHPLC system (Duisburg, Germany)
97 equipped with two binary pumps (LC-30AD) and proportionating valves, degassers (DGU-20A_{SR}),
98 autosampler with cooling capabilities (SIL-30AC), Prominence column oven (CTO-20AC), diode array
99 detector (SPD-M30A) and communication bus module (CBM-20A). A Shimadzu single quadrupole
100 Mass Spectrometer (LCMS 2020) was used as a secondary detector with positive electrospray
101 ionisation. The LC configuration had a dwell volume of 342 μ L and system retention volume of 14 μ L
102 [11].

103

104 *2.3 Stationary Phases*

105 All columns were new as supplied by the manufacturer and used a standardised column format of
106 150 x 2.1 mm. The Peptide RPC Column Characterisation database was expanded using 43 stationary
107 phases from several column manufacturers, which differed by ligand chemistry, pore size and base
108 silica. The database is available from the corresponding author upon request. A brief description of
109 each of the phases assessed can be located in Table 1. The peak apex of a water injection was used as
110 the dead time marker [11].

111

112 *2.4 Column Characterisation Protocols*

113 The description of the procedure for the Peptide RPC Column Characterisation protocol and
114 mitigation to ensure the integrity of the protocol are all described within reference [10] in Appendix
115 1. The Peptide RPC Column Characterisation Protocol was compared against the extended Tanaka
116 protocols and Snyder's Hydrophobic Subtraction Model which are well described within literature [1-
117 4, 6, 7, 12-15].

118

119 *2.5 Protein Digests*

120 Trypsin was added to either carbonic anhydrase or bovine insulin (all 0.4 mg/mL) in a ratio of 1:20
121 respectively, and dissolved in 50 mM TRIS buffer pH 7.5 (7.4 mM TRIS base and 42.6 mM TRIS HCl).
122 The solutions were stored at 37 °C for 24 hours. The digestion was stopped by the addition of 37%
123 HCl to reduce the pH to 2.5 (3 mL HCl was added to 20 mL of sample). The digest was
124 chromatographed using either low or intermediate pH. The low pH conditions used 0.1% formic acid
125 in water for the aqueous component and 0.1% v/v formic acid in acetonitrile for the organic
126 component. The intermediate pH conditions used 20 mM ammonium formate in water for the

127 aqueous and pure acetonitrile for the organic component. The gradient for both mobile phases was
128 as follows: 5-60 %B over 60 minutes, where it was held at 60%B for 2 minutes, before dropping to
129 initial conditions in 0.1 minutes, and re-equilibrated for 12 minutes (equivalent to 10 column
130 volumes). The gradients were performed on a range of columns selected to give very similar or
131 different selectivity based on PCA (see Section 3.4 below). Analyses were performed at 40 °C and 0.3
132 mL/min flow rates.

133

134 *2.6 Software and Calculations*

135 The LC instrument was controlled and data processing performed using LabSolutions (Version 5.86,
136 Shimadzu, Duisburg, Germany). Principal Component Analysis (PCA) was performed using SIMCA
137 (Version 14.1, Umetrics, Umeå, Sweden) and Origin (Version OriginPro 2016, OriginLab,
138 Northampton, MA, USA). The net charges of the peptide probes were calculated at both pH 2.5 and
139 6.45 using General Protein / Mass Analysis for Windows (GPMAW) software (Version 9.51,
140 Lighthouse Data, Odense, Denmark).

141

142 **3 Results / Discussion**

143 *3.1 Principal Component Analysis*

144 Each stationary phase was assessed using nine peptide probes; three from the 1-15 portion of Bovine
145 GLP-2, and six from the 16-33 portion of Bovine GLP-2, all nine probes differed by just one amino acid
146 residue in order to evaluate subtle selectivity differences of the stationary phases towards these
147 probes. The full 33 amino acid sequence had the propensity to form higher order structures, thus the
148 sequence was divided into two, where the first base sequence contained amino acids 1-15 and the
149 second contained amino acids 16-33 (Bovine-GLP-2 (1-15) and Bovine-GLP-2 (16-33)). Selectivity
150 (referred to as delta, Δt_g^*) was determined by the normalised retention difference ([9, 10]) between
151 certain modified peptides and its corresponding original base sequence (either Peptide Numbers 1 or
152 13, Table 2). The delta values enabled evaluation of the effect of oxidation, changes in negative
153 charge, steric interactions such as racemisation and switches in amino acid sequence, aromatic and
154 phenolic interactions and changes in positive charge. Initial studies using circular dichroism deduced
155 there was a lack of secondary structure of the peptides within the mobile phase. However, it was
156 later found that the selectivity differences observed could only be explained by the presence of a
157 second order structure of the peptides within the hydrophobic acetonitrile / ligand layer of the
158 stationary phase [9, 16-18].

159 Delta values for each of the stationary phases were collated and evaluated using PCA. Approximately
160 82% of the variability was described using two principal components. The addition of a third principal
161 component contributed with an additional 10% but complicates visual comparisons. It was therefore
162 decided to limit the number of principal components to two. Each stationary phase was assigned a
163 classification based on prior knowledge of the phase chemistry and location in the PCA score plot.
164 The score plot in Fig. 1A demonstrates that there are regions of high electrostatic interactions
165 (positive and negative) and a region of low electrostatic / polar interactions. The negative / polar
166 stationary phase character, predominantly in the upper right quadrant of the score plot, also aligns
167 itself with the increase in positive charge probe, $\Delta(26,13)$ AF, the changes in aromatic / phenolic
168 character probe, $\Delta(24,13)$ AF and oxidation probe, $\Delta(8a,1)$ FA (Fig. 1B). It is possible that the $\Delta(26,13)$
169 AF probe is more important in identifying stationary phases with negative character in comparison to
170 $\Delta(26,13)$ FA due to the presence of negatively charged silanol groups at intermediate pH. The
171 aromatic / phenolic character probe could potentially distinguish phases which can form hydrogen
172 bonds with the hydroxyl group of the tyrosine substituent, form *pi-pi* interactions with aromatic
173 ligand moieties, or potentially could differentiate phases based on steric interactions, where the
174 larger tyrosine amino acid might alter the secondary structure of the peptide within the hydrophobic,
175 acetonitrile layer in the stationary phase [9, 16, 17]. The oxidised probe is also capable of forming
176 hydrogen bonds with accessible silanol groups at low pH, thus its position within the loading plot can
177 also be rationalised. The region of low electrostatic interactions in the lower right quadrant can be
178 characterised by high $\Delta(15,13)$ AF and $\Delta(16,13)$ FA, which mostly assess steric interactions. $\Delta(26,13)$
179 FA is also located in the lower right quadrant, where its position is less obvious to interpret. The
180 stationary phases possessing positively charged functional groups are in the upper and lower left
181 quadrants of the score plot which aligns with the increase in negative charge probe, $\Delta(9,1)$ FA, in the
182 loading plot (Fig. 1B).

183 The neutral grouping in the lower right quadrant consists of a plethora of phases with alkyl moieties
184 with high ligand density and end capping. These phases (green circles) include the C18 alkyl ligand
185 phases, but also the Acquity BEH C8, Poroshell HPH C8 and Kinetex C8. One exception to the cluster
186 of neutral phases is the location of the Kinetex C18, which was positioned within the negative / polar
187 phases, close to the Poroshell SB-AQ. This position was affirmed by evaluation of a brand-new
188 column. Comparison of the Kinetex C18 against other C18 alkyl phases using PCA, based on the
189 extended Tanaka protocol or the Hydrophobic Subtraction Model data, did not indicate any potential
190 rationale for its divergence in the current study. Hence, it is unclear why the Kinetex C18 displays
191 more polar properties in the peptide characterisation compared to other C18 columns. It is
192 interesting to note that during peptide analysis within Novo Nordisk, the Kinetex C18 column has

193 been found to display different selectivities compared to other C18 columns on numerous occasions
194 (unpublished results).

195 The blue square markers in the upper right quadrant denote the negative / polar phases. These
196 consist of phases which either possess a negative moiety in the ligand chemistry and / or contain
197 significant silanophilic interactions by means of low ligand density or no end capping, or a ligand
198 architecture which can promote access to the silica surface. The group contains phenyl phases such
199 as phenyl hexyl, diphenyl and biphenyl phases, where the ligand architecture is such that the peptide
200 probe can potentially gain accessibility to the silica surface and its silanol groups [19, 20]. There are
201 also two pentafluorophenyl phases which, in addition, have the ability to form electrostatic *pi-pi*
202 interactions. This category also contains the Acquity HSS C18-SB, Acquity BEH C4, Poroshell SB-AQ,
203 Zorbax SB-C8, Zorbax SB-C18 and Zorbax SB-C18 300 which are all non end capped phases and
204 possess low ligand density, properties which promote silanol interactions. Although the Acquity BEH
205 C4 has reduced hydrophobic interactions due to the shorter alkyl chain and is non end capped, it is
206 actually located within the neutral alkyl phases. This is perhaps contrary to expectations but the
207 phase is based on hybrid silica with fewer silanol groups to interact with the solutes. In addition,
208 smaller ligands normally yield a higher surface coverage compared to C18 type columns. The PLRP-S
209 is a hydrophobic polymeric phase with no silanol groups. However, its position within the score plot
210 would suggest there are either polar or negative retention mechanisms which this phase can
211 undertake. This could be attributed to either the presence of negatively charged cation-exchange
212 sites on the phase as suggested for the Hamilton PRP-1 [21] or a cation- π aromatic interaction
213 between the benzene functionality of the stationary phase and the positively charged peptide [22].
214 The Acclaim WCX is a mixed mode stationary phase with a carboxylic acid moiety. The Acclaim WCX
215 was not included in the PCA due to repulsion of the hydrophilic peptides which possessed a negative
216 net charge from the deprotonated carboxylic acid ligand at intermediate pH conditions. However,
217 the negatively charge carboxylic acid using ammonium formate at native pH would suggest this type
218 of phase would be located within the negative / polar character group. At low pH the Acclaim WCX
219 behaves like a C-alkyl phase because of the protonated carboxylic acid terminal ligand.

220 The stationary phases with positively charged functionalities were scattered within the upper and
221 lower left quadrants of the score plot and consisted of the Acquity CSH range, the Luna Omega PS
222 C18, the Poroshell 120 Bonus-RP and the Polaris Amide C18. These phases were characterised using
223 the extended Tanaka protocols where positive character can be measured using the selectivity
224 between benzene sulfonic acid and toluene ($\alpha_{(BSA/T)}$). The negatively charged benzene sulfonic acid
225 was retained on all the phases, which suggests positive character on the phase. These results would
226 imply that the Polaris Amide C18 and the Poroshell Bonus-RP were both synthesised in a two-step

227 process where unreacted / non-acylated amino groups are positively charged, thus capable of
228 electrostatic interactions [13]. The CSH range and the Luna Omega PS C18 have all been designed to
229 possess a low amount of positive surface charge in order to improve peak shape of positively charged
230 compounds at low pH and low ion strength [20, 23].

231 It should be noted the Ascentis Express F5, Bioshell CN, Bioshell C18 and AdvanceBio Peptide Map
232 were not included in the PCA. The Ascentis Express F5 retained the multiple positively charged
233 peptides in ammonium formate which was initially hypothesised due to the dense electronegative
234 charge associated with the fluorinated aromatic ring. However, this was not an issue for the Kinetex
235 F5 or Poroshell PFP which possess similar characteristics for aromatic and dipole character to the
236 Ascentis Express F5 based on the Extended Tanaka protocol. There is greater silanophilic activity on
237 the Ascentis Express F5, as highlighted from the Extended Tanaka protocol results for $\alpha_{(B/P, pH 7.6)}$ and
238 $\alpha_{(B/P, pH 2.7)}$, which could possibly help elude to the added retention of the positively net charged
239 peptides in ammonium formate. The Bioshell CN could be characterised using the formic acid
240 conditions, which exhibited typical peak shapes. Whilst the hydrophobic peptides could be
241 satisfactorily retained under the ammonium formate conditions, the hydrophilic peptides eluted in
242 the void. This prevented the determination of t_g^* and consequently Δt_g^* . The diisopropylcyanopropyl
243 phase has limited hydrophobicity due to the short alkyl linker, thus there is insufficient
244 hydrophobicity to retain the hydrophilic peptides. The silanophilic interaction under intermediate pH
245 conditions ($\alpha_{(Benzylamine/Phenol @ pH 7.6)}$) measured in the Extended Tanaka protocol also suggests there is
246 some negative character to the phase, which could also explain the lack of retention of the negatively
247 net charged hydrophilic peptides. Conversely, the peptides were eluted from the Bioshell C18 and
248 AdvanceBio Peptide Map within the given gradient time in ammonium formate. However, under
249 formic acid conditions, the hydrophobic peptides could not be eluted from the stationary phase. The
250 gradient was extended to 100% MeCN with the corresponding %B/min change used on the original
251 gradient without success. This would suggest the phases possess significant hydrophobicity, making
252 them potentially more suitable for less hydrophobic peptides, whilst the Bioshell CN is better suited
253 to more hydrophobic compounds. In comparison, all peptides eluted on the Bioshell C18 and
254 AdvanceBio Peptide Map when TFA was employed as the additive. This is difficult to rationalise as
255 TFA is a more hydrophobic ion pair than formic acid. The AdvanceBio Peptide Map yielded excellent
256 peak shapes for all the peptides with TFA. Consequently, 38 stationary phases were characterised
257 and not the original 43.

258 The use of PCA enables the user to visualise the difference or similarities between stationary phases.
259 For example, phases which are located within close proximity are presumed to possess similar
260 chromatographic selectivity, whilst those which are separated can be viewed as chromatographically

261 diverse. This can help to direct the design of new silanes for stationary phases. It is clear that
262 although hydrophobic interactions dominate the retention mechanisms in reversed phase
263 chromatography, there are also other interactions which are important, namely polar and
264 electrostatic interactions.

265 Phases which could incorporate some form of charge or polar functionality could be of particular
266 interest for peptide chromatography specialists. Some of the most diverse selectivity was achieved
267 on phases which can incorporate these types of interactions, such as the Polaris Amide C18, Acquity
268 CSH Fluoro Phenyl and the Acclaim WCX. These phases are capable of electrostatic and / or polar
269 interactions with the peptides, with different modes of interactions possible depending on pH. These
270 columns were compared against the neutral Ascentis Express C18 phase, using stick plots of the
271 characterisation data in both formic acid or ammonium formate (Fig. 2). The Ascentis Express C18
272 was selected to represent a standard C18 type stationary phase. The comparison demonstrates the
273 different retentivity of charged peptides on phases with positive or negative character. The Ascentis
274 Express C18 (Fig. 2D) is a neutral phase with little acidic silanol activity, thus the mode of interaction
275 between the stationary phase and peptide is mainly hydrophobic. The Acclaim WCX possessed a
276 similar elution profile under formic acid conditions to the neutral C18 phase which suggests retention
277 is primarily related to the alkyl proportion of the WCX ligand functionality. [Tyr26]-Bovine GLP-2
278 (Peptide Number 24) possessed greater relative retentivity on the Acclaim WCX compared to the
279 Ascentis Express C18 which is possibly indicative of polar interactions between the polar carboxylic
280 acid moiety and the tyrosine substituted peptide such as hydrogen bonding. The Acquity CSH Fluoro
281 Phenyl and the Polaris Amide C18 (Fig. 2B and C respectively) possessed similar retentivity for the
282 majority of peptides, where the more positively charged [Gly22]-, [Tyr26]- and [Lys26]-Bovine GLP-2
283 (16-33) (Peptide Numbers 16, 24 and 26, respectively) were repulsed from the positive character
284 stationary phases in comparison to Bovine GLP-2 (1-15) and [L-Asp11]-Bovine GLP-2 (Peptide
285 Numbers 1 and 9, respectively). The change in relative retention for the peptide [Lys26]-Bovine GLP-
286 2 (16-33) (Peptide Number 26) was to a greater degree than the other peptides due to the greater
287 positive net charge (Table 2). The more positively charged hydrophobic peptides experience a greater
288 repulsion on the Polaris Amide C18 which has a higher degree of positive charge on the ligand, thus
289 having a narrower elution window. This is also evident from the extended Tanaka protocol, where
290 the negatively charged benzene sulfonic acid was greatly retained on the Polaris Amide C18 [13].

291 Under intermediate pH conditions, the Acclaim WCX was negatively charged, which caused the
292 negatively charged hydrophilic peptides to elute on the void. [Lys26]-Bovine GLP-2 (16-33) (Peptide
293 Number 26) possessed significant increases in retentivity on the Acclaim WCX in comparison to the
294 remaining peptides due to the positive net charge of the peptide and the fully charged WCX ligand or

295 accessibility into the stationary phase, and selectivity was notably different to other stationary
296 phases evaluated. The Polaris Amide C18 and the Acquity CSH Fluoro Phenyl, whilst
297 chromatographically similar at low pH, demonstrated significant selectivity differences under
298 intermediate pH conditions. The positive character on the Polaris Amide C18 was still present, as
299 demonstrated by the low relative retention of [Lys26]-Bovine GLP-2 (16-33) (Peptide Number 26),
300 whilst the negative charged Bovine GLP-2 (1-15) and [L-Asp11]-Bovine GLP-2 (1-15) (Peptide Number
301 1 and 9) had greater retentivity in comparison to the other phases under the same conditions. The
302 selectivity on the Acquity CSH Fluoro Phenyl, on the other hand, seemed to resemble the Acclaim
303 WCX which suggests a greater degree of negative character on the stationary phase. This could be
304 due to the non end capped silica which results in a higher number of negatively charged silanol
305 groups at intermediate pH causing repulsion of the negatively charged peptides, and greater
306 retention of the positive net charge of [Lys26]-Bovine GLP-2 (16-33) (Peptide Number 26).

307 The peptide [Lys26]-Bovine GLP-2 (16-33) (Peptide Number 26) was compared in both formic acid
308 and ammonium formate on the four phases in Fig 2. The peak shape on the C18 phase under
309 ammonium formate conditions was significantly improved compared to the low pH conditions, (peak
310 width decreased from 0.107 to 0.052), as expected with the low ionic strength of the formic acid and
311 the multiply charged peptide. The amide phase gave good peak shape under both mobile phase
312 conditions with peak widths of 0.054 and 0.074, which demonstrates the usefulness of the phase
313 with positive character with low ionic strength additives like formic acid. The fluoro phenyl phase
314 also produced similar peak widths under both mobile phase conditions (0.100 and 0.093), but
315 exhibited broader peaks compared to the amide. The WCX phase produced peak widths of 0.154 and
316 0.161, under low and intermediate pH, respectively. Note type of particle as well as particle sizes
317 differ between these phases as described in Fig. 2.

318 The score plot in Fig. 1A suggests an empty space in the upper left quadrant which could be occupied
319 by a mixed mode phase with positive character to give a selectivity which is completely different to a
320 standard C18 column whilst maintaining an excellent peak shape (See Section 3.2 for a discussion on
321 the peak capacity). Despite the selectivity potential for mixed mode phases, the successful
322 implementation within the laboratory depends on the batch to batch reproducibility, which has been
323 poor for many traditional SCX, WCX and mixed alkyl / SCX or WCX phases. Newer mixed mode phases
324 would need to be evaluated for batch to batch reproducibility, but they are likely to offer an
325 interesting alternative selectivity for stationary phase development as shown in the current study.

326

327 *3.2 Peak Capacity*

328 The sample peak capacity (PC^{**}) was used to measure the performance of the separation in both
329 formic acid and ammonium formate, which calculates the number of peaks that can be separated
330 between the first and last eluting analyte in a sample (Eq. 1) [24]. This measurement was selected to
331 represent the performance for a particular stationary phase in the retention window.

$$332 \quad PC^{**} = \frac{t_{g\max} - t_{g\min}}{w_{ave}} + 1 \quad \text{Eq. 1}$$

333 Where $t_{g\min}$ and $t_{g\max}$ are the retention times of the first and last eluting peptide and w_{ave} is the
334 average width at base for all the peaks that are separated except for the diastereoisomeric oxidised
335 methionine probes (Peptide Number 8) which are typically poorly separated on most of the
336 stationary phases. The average peak width and the retention time for the first and last eluting
337 peptide are recorded in the supplementary material.

338 The PC^{**} values for the stationary phases in formic acid ranged between 22-155 (mean 91) whilst the
339 ammonium formate conditions provided a range of 72-272 (mean 189), which illustrates the
340 increased performance which can be generated when using ammonium formate in comparison to
341 formic acid. The Acclaim WCX, PLRP-S and Polaris Amide C18 stationary phases generated PC^{**} of 50,
342 64 and 83 using the formic acid conditions, respectively, whilst the ammonium formate conditions
343 generated a value of 72 on the Polaris Amide C18. It should be noted that these phases had a greater
344 particle size compared to most other phases assessed (totally porous particle (TPP) 3 μm versus TPP
345 1.8 μm or 2.7 superficially porous particle (SPP)). It is therefore expected that peak capacity should
346 increase by approx. 1.4x when reducing the particle size.

347 The ammonium formate in the aqueous portion of the mobile phase was 20 mM which is sufficient
348 to improve peak shape by reducing mutual repulsion effects. McCalley *et al.* suggested that the poor
349 peak shape often observed for basic species, such as the positively charged peptides used in this
350 study, is related to overloading caused by mutual repulsion between adsorbed ions of the same
351 charge [21, 25, 26]. Mobile phases such as formic acid exacerbate this issue because there is
352 insufficient ionic strength, where a 0.1% formic acid v/v solution has approximately 2 mM ionic
353 strength in comparison to 20 mM ionic strength for a 20 mM ammonium formate solution. Formic
354 acid mobile phases can, however, produce acceptable levels of peak capacity for phases which
355 possess some positive charge, such as the Polaris Amide C18, the CSH range of stationary phases and
356 the Luna Omega PS C18 [23]. These phases can produce improved peak shapes for basic species,
357 where the peak width at 50% and asymmetry factor at 10% decreased on average for the positive
358 character stationary phases by 43 and 24%, respectively between formic acid and ammonium
359 formate (data not shown). This contrasted with the neutral and negative character stationary phases,

360 which increased in peak width by 37% on average between formic acid and ammonium formate, and
361 tailing increased by 30% on average between the two mobile phases.

362 The PC^{**} value observed on the Polaris Amide C18 was lower than expected despite narrow peak
363 widths. This was attributed to a narrower elution window compared to the other phases, where the
364 elution window was 27 and 32% smaller on average in formic acid and ammonium formate,
365 respectively. This is a potential limitation of the PC^{**} measure, which can present a false impression
366 of the results if the elution window is narrower than comparative columns. However, this can be
367 addressed by applying the conventional peak capacity (PC – Equation 2) equation to all the stationary
368 phases, where the two different measurements complement each other to provide an overview of
369 the chromatographic performance. The PC values in formic acid ranged between 71-561 (mean 297)
370 whilst ammonium formate ranged between 122-470 (mean 341). The Polaris Amide C18's PC values
371 increased to 421 in formic acid and 173 in ammonium formate. There are limitations in both PC^{**} and
372 PC measurements, where the former can underestimate the value due to a narrow elution window,
373 whereas the latter can overestimate the separation power, as peaks do not elute across the entire
374 gradient time. However, when used in conjunction, they can accurately represent the
375 chromatographic performance of the stationary phase.

$$376 \quad PC = \frac{t_G}{w_{ave}} + 1 \quad \text{Eq. 2}$$

377

378 Where t_G is the gradient time for the linear gradient.

379

380 *3.3 Comparison of the Peptide RPC Column Characterisation Protocol against protocols based on* 381 *small molecules*

382 The Peptide RPC Column Characterisation Protocol was devised to bridge the deficit in column
383 characterisation approaches for stationary phases used for peptide separations, where it is believed
384 that probes which represent the analytes of interest are best suited for characterising the stationary
385 phase. However, it is important to compare and contrast results produced by the peptide protocol
386 against small molecule column characterisation protocols in order to evaluate its necessity. The small
387 molecule databases are vast with nearly 400 columns characterised by the extended Tanaka protocol
388 and over 600 columns characterised by the Hydrophobic Subtraction Model. Therefore, logically the
389 larger databases would be used to compare columns if there was a correlation. Small molecule
390 characterisation data was obtained from Snyder's Hydrophobic Subtraction Model (HSM) via the

391 PQRI database [5] with the expanded version on the web [7], the Tanaka protocol in the ACD
392 database, and experimental results for the extended Tanaka protocol [3, 5, 7, 13]. Although 38
393 columns were successfully characterised using the peptide approach, the comparison was limited to
394 30 stationary phases which were common between all three databases (see Table 1). The
395 characterisation data for these 30 columns on the three different protocols were combined into a
396 single loading plot, where the locations of the different terms were observed (Fig. 3). The closely
397 located terms highlight a greater correlation compared to terms with larger spacing.

398 The results from the peptide protocol were compared against the two small molecule approaches
399 which indicated that there were some weak correlations, particularly for electrostatic types of
400 interactions (i.e. $\Delta(26,13)$ FA and C(2.8) or $\alpha_{(B/P) \text{ pH } 2.7}$ and $\Delta(9,1)$ FA and $\alpha_{BSA/T}$, Fig. 3). The correlation
401 between probes were also compared pairwise using traditional linear regression analysis (Table 3).
402 The resulting R^2 values varied between 0.15 – 0.75 and 0.32 – 0.73 between the delta values and the
403 Tanaka terms, and the delta values and HSM terms, respectively (Table 3). The Polaris Amide C18
404 possessed extreme properties in all three characterisation protocols, which caused the phase to be
405 distinct from other phases. With the Polaris Amide C18 excluded in the comparison, the regression
406 coefficients were reduced with R^2 values between 0.10 – 0.45 and 0.20 – 0.41, respectively. This is
407 due to the extreme properties attributed to the positively charged functionality on the ligand which
408 skewed the relationship analysis.

409 The results essentially show that there is no correlation between the Peptide RPC Column
410 Characterisation Protocol and the Hydrophobic Subtraction Model or the extended Tanaka protocol.
411 Thereby it proves that there is a need for a RPC column characterisation protocol based on peptide
412 probes.

413

414 **3.4 Validation of the Protocol**

415 Tryptic digests of carbonic anhydrase and bovine insulin were made in order to generate peptide
416 fragments which could be tracked for selectivity differences. The aim was to establish if the Peptide
417 RPC Column Characterisation database could be used to select stationary phases with diverse
418 selectivity thus producing a different chromatographic profile. It was previously demonstrated that
419 the protocol can be used to find columns with different and similar selectivity for different purposes.
420 However, the same peptides were used to characterise the stationary phases as well as illustrate
421 differences and similarities with respect to selectivity [9]. In the current study based on the tryptic

422 digests of bovine insulin and carbonic anhydrase, completely different peptides were used for the
423 validation which would be more appropriate.

424 The Polaris Amide C18, Zorbax 300 SB-C18, Acquity BEH C8, Ascentis Express C18, Kinetex Biphenyl,
425 Acquity CSH C18 and Acquity CSH Fluoro Phenyl were all identified as being chromatographically
426 dissimilar via the score plot in Fig. 1A. Eleven carbonic anhydrase fragments were monitored using
427 mass spectrometry with ions selected via extracted ion chromatograms (EIC) on the six columns
428 using the formic acid additive conditions described in Section 2.5 (Fig. 4). There are clear selectivity
429 differences between the six phases, with the elution order differing between all six phases as well as
430 the degree of resolution between peaks. The Ascentis Express C18, Zorbax 300 C18-SB and Acquity
431 BEH C8 were all categorised as neutral phases, but all demonstrated different elution profiles, which
432 illustrates that phases within the same classification can bestow alternative selectivity. The
433 differences in intensity observed for certain fragments can be explained by signal suppression caused
434 by co-eluting fragments which are not displayed. In addition to the different selectivity, the Acquity
435 CSH C18 and Polaris Amide C18 both reveal superb peak shape using formic acid conditions.

436 Selectivity can also be measured between two chromatographic conditions (i.e. two different
437 columns or mobile phases) by plotting the retention time of a set of compounds to derive the
438 regression coefficient (R^2) [27, 28]. The R^2 value can be inserted into Eq. 3 to determine the
439 selectivity correlation, where a S value of 0 signifies identical selectivity, whilst a value of 100
440 identifies orthogonal selectivity.

$$441 \quad S = 100 \sqrt{1 - R^2} \quad \text{Eq. 3}$$

442

443 This approach was applied to the retention times of digest fragments, where each column in Fig. 4
444 was compared directly to the Ascentis Express C18, as a typical C18 phase. Results greater than 10
445 would typically suggest there are selectivity differences between the two parameters [28]. The S
446 values (Fig. 4) were all greater than 11, with the largest differences achieved between the Polaris
447 Amide C18 and the Ascentis Express C18 ($S = 33$), which is quite significant.

448 As important as choosing stationary phases with different selectivity, it is often crucial to identify
449 phases with similar selectivity. The following phases were identified as potentially providing similar
450 selectivity profiles from the score plot (Fig. 1A); Ascentis Express C18 and Poroshell HPH-C18, the
451 Acquity CSH C18 and Luna Omega C18 PS, and finally Kinetex Biphenyl and Ascentis Express Biphenyl.
452 A tryptic digest of carbonic anhydrase was chromatographed using the formic acid gradient
453 conditions described for the peptide characterisation protocol (Fig. 5). The Poroshell HPH-C18 and

454 Ascentis Express C18 were superimposed in the score plot (Fig. 1A), and clearly demonstrate a very
455 similar eluting profile for the peptide fragments. The order of elution as well as the resolution
456 between peaks are extremely similar. The Ascentis Express Biphenyl and Kinetex Biphenyl were
457 within close proximity to one another in the score plot (Fig. 1A) and also contain a similar ligand
458 moiety. In general, the elution profile is very similar, with some subtle differences between the peaks
459 (see peaks 9-11). The final pair, the Luna Omega PS C18 and Acquity CSH C18, have an alkyl moiety
460 with some degree of positive charge on the surface of the phase. Their location within the score plot
461 (Fig. 1A) suggest that some similarity could be expected but also that there are some differences as
462 their positions are not overlaid. The profiles in Fig. 5 confirms that this is the case, where in general,
463 the elution profile is similar but there also are selectivity differences between some of the critical
464 pairs. The selectivity correlation was applied to the set of columns, where the Poroshell HPH-C18 was
465 compared to the Ascentis Express C18, the Ascentis Express Biphenyl was correlated against the
466 Kinetex Biphenyl and the Luna Omega PS C18 was evaluated against the Acquity CSH C18. The S-
467 values ranged between 2 and 8, which all demonstrate a close correlation between the predicted
468 pair of similar columns.

469 Similar selectivity differences were observed for the digest of carbonic anhydrase chromatographed
470 at mid pH as well as for the tryptic digest of bovine insulin. Overall, the score plot was successfully
471 used to select stationary phases which could be chromatographically dissimilar with a diverse elution
472 profile or can be used to select phases with similar profiles.

473

474 **4 Conclusions**

475 A novel column characterisation protocol which employed peptides as probes was applied
476 successfully to 38 out of 43 stationary phases. The results were placed in a database and critically
477 assessed using principal component analysis. Each phase was classified into one of three groups;
478 neutral, negative / polar or positive character, where the column classification was justified based on
479 its position within the score plot and prior knowledge of the phase. This approach allows easy
480 identification of phases which could be chromatographically similar or dissimilar, depending on its
481 location relative to another column.

482 This protocol facilitates the identification of potential novel stationary phases which could provide
483 alternative selectivity for method development strategies. The study suggests that phases which
484 offer different selectivity and good peak shape for peptides also often possess electrostatic
485 interactions. In particular, mixed mode phases possessing some form of positive moiety show great
486 potential, provided good batch to batch reproducibility also can be obtained.

487 The results of the Peptide RPC Column Characterisation Protocol were compared against two
488 protocols based on small molecule which highlighted a lack of correlation between the test
489 parameters. Consequently, there is a need for a peptide-based protocol to select appropriate
490 stationary phases for peptide separations.

491 Finally, the use of stationary phase peptide database to select columns of similar and dissimilar
492 chromatographic selectivities at low and mid pH was proven using tryptic digests. Further work is
493 currently underway to expand the protocol to also cover mobile phases.

494

495 5 References

- 496 1. M.R. Euerby and P. Petersson, *Chromatographic classification and comparison of*
497 *commercially available reversed-phase liquid chromatographic columns using principal*
498 *component analysis*. J. Chromatogr. A., 2003. 994: p. 13-36.
- 499 2. K. Kimata, K. Iwaguchi, S. Onichi, K. Jinno, R. Eksteen, K. Hosoya, M. Araki, and N. Tanaka,
500 *Chromatographic characterisation of silica C18 packing materials. Correlation between a*
501 *preparation method and retention behaviour of stationary phase*. J. Chromatogr. Sci., 1989.
502 27: p. 721-728.
- 503 3. *ACD/Labs Column Selector*. 10/07/2019]; Available from:
504 <http://www.acdlabs.com/resources/freeware/colsel/index.php>.
- 505 4. L.R. Snyder, J.W. Dolan and P.W. Carr, *The hydrophobic subtraction model of reversed-phase*
506 *column selectivity*. J. Chromatogr. A., 2004. 1060: p. 77-116.
- 507 5. *U.S. Pharmacopeial Convention*. 10/07/2019]; Available from:
508 <http://apps.usp.org/app/USPNF/columnsIntro.html>.
- 509 6. A. R. Johnson, C.M. Johnson, D.R. Stoll and M.F. Vitha, *Identifying orthogonal and similar*
510 *reversed phase liquid chromatography stationary phases using the system selectivity cube*
511 *and the hydrophobic subtraction model*. J. Chromatogr. A., 2012. 1249: p. 62-82.
- 512 7. D. Stoll. *HPLC columns - HPLC column selectivity measurements of more than 600 reversed*
513 *phase columns from over 30 manufacturers*. 10/07/2019]; Available from:
514 <http://www.hplccolumns.org/about/index.php>.
- 515 8. C.T. Mant and R.S. Hodges, *Design of peptide standards with the same composition and*
516 *minimal sequence variation to monitor performance / selectivity of reversed-phase matrices*.
517 J. Chromatogr. A., 2012. 1230: p. 30-40.
- 518 9. J.K. Field, M.R. Euerby, P. Petersson, J. Lau and H. Thøgersen, *Investigation into reversed-*
519 *phase chromatography peptide separation systems part I: Development of a protocol for*
520 *column characterisation*. J. Chromatogr. A., 2019. 1603: p. 113-129.
- 521 10. J.K. Field, M.R. Euerby and P. Petersson, *Investigation into reversed-phase chromatography*
522 *peptide separation systems Part II: An evaluation of the robustness of a protocol for column*
523 *characterisation*. J. Chromatogr. A., 2019. 1603: p. 102-112.
- 524 11. P. Petersson, B.O. Boateng, J.K. Field and M.R. Euerby, *A practical approach to modelling of*
525 *reversed-phase liquid chromatographic separations: Advantages, principles and possible*
526 *pitfalls*. LCGC Europe, 2018. 31: p. 120-143.
- 527 12. M.R. Euerby, P. Petersson, W. Campbell and W. Roe, *Chromatographic classification and*
528 *comparison of commercially available reversed-phase liquid chromatographic columns*
529 *containing phenyl moieties using principal component analysis*. J. Chromatogr. A., 2007.
530 1154: p. 138-151.

- 531 13. M.R. Euerby and P. Petersson, *Chromatographic classification and comparison of*
532 *commercially available reversed-phase liquid chromatographic columns containing polar*
533 *embedded groups / amino endcappings using principal component analysis.* J. Chromatogr.
534 A., 2005. 1088: p. 1-15.
- 535 14. J.W. Dolan, A. Maule, D. Bingley, L. Wrisley, C.C. Chan, M. Angod, C. Lunte, R. Krisko, J.M.
536 Winston, B.A. Homeier, D.V. McCalley, and L.R. Snyder, *Choosing an equivalent replacement*
537 *column for a reversed-phase liquid chromatographic assay procedure.* J. Chromatogr. A.,
538 2004. 1057: p. 59-74.
- 539 15. N.S. Wilson, M.D. Nelson, J.W. Dolan, L.R. Snyder, R.G. Wolcott, and P.W. Carr, *Column*
540 *selectivity in reversed-phase liquid chromatography I. A general quantitative relationship.* J.
541 Chromatogr. A., 2002. 961: p. 171-193.
- 542 16. S. Bocian, A. Felinger and B. Buszewski, *Comparison of solvent adsorption on chemically*
543 *bonded stationary phases in RP-LC.* Chromatographia, 2008. 68: p. s19-s26.
- 544 17. S. Bocian, P. Vajda, A. Felinger and B. Buszewski, *Solvent excess adsorption on the stationary*
545 *phases for reversed-phase liquid chromatography with polar functional groups.* J.
546 Chromatogr. A., 2008. 1204: p. 35-41.
- 547 18. S.M. Melnikov, A. Höltzel, A. Seidel-Morgenstern and L. Tallarek, *Adsorption of water-*
548 *acetonitrile mixtures to model silica surfaces.* J. Phys. Chem. C., 2013. 117: p. 6620-6631.
- 549 19. A. Méndez, E. Bosch, M. Rosés and U.D. Neue, *Comparison of the acidity of residual silanol*
550 *groups in several liquid chromatography columns.* J. Chromatogr. A., 2003. 986: p. 33-44.
- 551 20. M. Gilar, K. Berthelette, K. Kalikova, D. Folprechtova, E. Tesarova, and B. Alden. *Pure mode or*
552 *mixed mode chromatography? in HPLC2019.* 2019. Milan, Italy.
- 553 21. S.M.C. Buckenmaier, D.V. McCalley and M.R. Euerby, *Overloading study of bases using*
554 *polymeric RP-HPLC columns as an aid to rationalisation of overloading on silica-ODS phases.*
555 Anal. Chem., 2002. 74: p. 4672-4681.
- 556 22. S.H. Giese, Y. Ishihama and J. Rappsilber, *Peptide retention in hydrophilic strong anion*
557 *exchange chromatography is driven by charged and aromatic residues.* Anal. Chem., 2018.
558 90: p. 4635-4640.
- 559 23. P.C. Iraneta, K.F. Wyndham, D.R. McCabe and T.H. Water. *A review of Waters hybrid particle*
560 *technology. Part 3. Charged Surface Hybrid (CSH) technology and its uses in liquid*
561 *chromatography.* 2011 11/07/2019]; Available from:
562 <http://www.waters.com/webassets/cms/library/docs/720003929en.pdf>.
- 563 24. L.R. Snyder and J.W. Dolan, *High performance gradient elution.* 2007, Hoboken, NJ: John
564 Wiley & Sons.
- 565 25. D.V. McCalley, *Study of overloading of basic drugs and peptides in reversed-phase high*
566 *performance liquid chromatography using pH adjustment of weak acid mobile phases*
567 *suitable for mass spectrometry.* J. Chromatogr. A., 2005. 1075: p. 57-64.
- 568 26. D.V. McCalley, *Overload for ionised solutes in reversed-phase high performance liquid*
569 *chromatography.* Anal. Chem., 2006. 78: p. 2532-2538.
- 570 27. U.D. Neue, J.E. O'Gara and A. Méndez, *Selectivity in reversed-phase separations. Influence of*
571 *the stationary phase.* J. Chromatogr. A., 2006. 1127: p. 161-174.
- 572 28. M.R. Euerby, M. Fever, J. Hulse, M. James, P. Petersson, and C. Pipe, *Maximisation of*
573 *selectivity in reversed-phase liquid chromatographic method development strategies.* LCGC
574 Europe, 2016. 29: p. 8-21.

575

576

577

578 **6 Figure Captions**

579 Fig. 1 A) Score and B) loading plot for 38 stationary phases characterised using the Peptide
580 RPC Column Characterisation Protocol. The different stationary phases have been grouped
581 and colour coded based on prior knowledge of stationary phase properties.

582 Fig. 2 Comparison of normalised retention of the three test mixtures used to characterise
583 the stationary phase in formic acid and ammonium formate on the (A) Acclaim WCX, (B)
584 Acquity CSH Fluoro Phenyl, (C) Polaris Amide C18, and (D) Ascentis Express C18. Peptide
585 Number 1: Bovine GLP-2 (1-15), 8a/b: [Met(O)10]- diastereoisomers, 9: [L-Asp11]-Bovine
586 GLP-2 (1-15), 13: Bovine GLP-2 (16-33), 14: [D-Ser14]-, 15: [Ile26,Leu27]-, 16: [Gly22]-, 24:
587 [Tyr26]-, 26: [Lys26]-Bovine GLP-2 (16-33). On the right hand side are overlaid
588 chromatograms of [Lys26]-Bovine GLP-2 (16-33) (Peptide Number 26) in formic acid (pink
589 trace) and ammonium formate (black trace).

590 Fig. 3 Loading plot containing the parameters from the Peptide RPC Column Characterisation
591 Protocol, Hydrophobic Subtraction Model and extended Tanaka protocol. Parameters which
592 are close together could show potential correlation whilst parameters which are at a
593 distance have a limited relationship.

594 Fig. 4 Extracted ion chromatogram of a tryptic digest of carbonic anhydrase analysed on six
595 stationary phases selected to demonstrate different chromatographic profiles.
596 Chromatographic conditions were as follows: A: 0.1% formic acid in water, B: 0.1% formic
597 acid in acetonitrile, 5-60%B over 60 minute gradient, 40 °C, 0.3 mL/min, 4 µL injection. *m/z*
598 1: 330.40, 2: 605.10, 3: 639.10, 4:509.75, 5: 577.75, 6: 487.75, 7: 549.10, 8: 839.10, 9:
599 759.10, 10: 802.40, 11: 787.10

600 Fig. 5 Extracted ion chromatograms of a tryptic digest of carbonic anhydrase analysed on
601 three pairs of stationary phases to demonstrate chromatographic similarities.
602 Chromatographic conditions were as follows: A: 0.1% formic acid in water, B: 0.1% formic
603 acid in acetonitrile, 5-60%B over 60 minute gradient, 40 °C, 0.3 mL/min, 4 µL injection. *m/z*
604 1: 330.40, 2: 605.10, 3: 639.10, 4:509.75, 5: 577.75, 6: 487.75, 7: 549.10, 8: 839.10, 9:
605 759.10, 10: 802.40, 11: 787.10

606

Stationary Phase Character

- Negative / Polar
- Neutral
- ▼ Positive

A




Fig 1A

Delta Value Character

- ◆ Aromatic
- ◆ Negative charge
- ◆ Oxidation
- ◆ Phenolic
- Positive Charge
- ★ Steric




Fig 1B




Fig 2




Fig 3











Fig 4


Poroshell HPH-C18
S = 4




Ascentis Express Biphenyl
S = 2




Luna Omega PS C18
S = 8



Ascentis Express C18



Kinetex Biphenyl



Acquity CSH C18




Fig 5

Table 1

Stationary phase characterised using the Peptide RPC Column Characterisation Protocol as described in the manufacturer

Column	Pore size (Å)	Particle size (µm)	Description as given by manufacturers	Manufacturer
Acclaim Mixed Mode WCX ⁺	120	3	A mixed mode ligand composed of an alkyl chain with carboxylic acid terminus	Thermo
Acquity UPLC Protein BEH C4	300	1.7	A non end capped, trifunctional C4 alkyl ligand bonded to ethyl bridged silica hybrid material	Waters
Acquity UPLC BEH C8*	130	1.7	An end capped, trifunctional C8 alkyl ligand bonded to ethyl bridged silica hybrid material	Waters
Acquity UPLC Peptide BEH C18*	130	1.7	An end capped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material	Waters
Acquity UPLC Peptide BEH C18	300	1.7	An end capped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material	Waters
Acquity UPLC BEH Shield RP18*	130	1.7	An end capped, monofunctional alkyl ligand with an embedded carbamide functionality bonded to ethyl bridged silica hybrid material	Waters
Acquity UPLC Peptide CSH C18*	130	1.7	An end capped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge	Waters
Acquity UPLC CSH Fluoro Phenyl	130	1.7	A non end capped, trifunctional pentafluorophenyl ligand bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge	Waters
Acquity UPLC CSH Phenyl Hexyl	130	1.7	An end capped, trifunctional C6 alkyl chain with a terminal phenyl functionality bonded to ethyl bridged silica hybrid material which possesses a low level positive surface charge	Waters
Acquity UPLC HSS C18*	100	1.8	An end capped, trifunctional C18 alkyl ligand	Waters
Acquity UPLC HSS C18 SB*	100	1.8	A non end capped, trifunctional C18 alkyl phase with low ligand density	Waters
Acquity UPLC HSS T3*	100	1.8	An end capped, trifunctional, 100% aqueous compatible C18 alkyl phase with reduce ligand density	Waters
AdvanceBio Peptide Map [†]	120	2.7	An end capped, densely bonded C18 alkyl ligand on superficially porous particle	Agilent
Ascentis Express Biphenyl*	90	2.7	An end capped, superficially porous particle with a biphenyl ligand	Supelco
Ascentis Express C8*	90	2.7	An end capped, superficially porous particle with a C8 alkyl ligand	Supelco
Ascentis Express C18*	90	2.7	An end capped, superficially porous particle with a C18 alkyl ligand	Supelco
Ascentis Express F5 [†]	90	2.7	An end capped, superficially porous particle with a pentafluorophenylpropyl ligand	Supelco
Ascentis Express Phenyl-Hexyl*	90	2.7	An end capped, superficially porous particle with a C6 alkyl chain and terminal phenyl functionality	Supelco
Ascentis Express RP-Amide*	90	2.7	An end capped, superficially porous particle with a polar embedded amide group in the alkyl ligand	Supelco
BIOshell A160 Peptide C18 [†]	160	2.7	A non end capped, superficially porous particle with C18 alkyl ligand	Supelco
BIOshell A160 Peptide CN [†]	160	2.7	A non end capped, superficially porous particle with a diisopropylcyanopropyl ligand	Supelco
Chromolith Performance RP-18e*			An end capped, monolithic C18 alkyl ligand	Merck
Cortecs UPLC T3	120	1.6	An end capped, trifunctional, 100% aqueous compatible C18 alkyl phase with reduce ligand density on a superficially porous particle	Waters

Fortis Diphenyl*	100	1.7	An end capped, diphenyl ligand	Fortis
Kinetex Biphenyl*	100	2.6	An end capped, superficially porous particle with a biphenyl ligand	Phenomenex
Kinetex C8*	100	2.6	An end capped, superficially porous particle with a C8 alkyl ligand	Phenomenex
Kinetex C18*	100	2.6	An end capped, superficially porous particle with a C18 alkyl ligand	Phenomenex
Kinetex Evo C18*	100	2.6	An end capped, superficially porous organo-silica particle with ethane cross linking and C18 alkyl ligand	Phenomenex
Kinetex F5*	100	2.6	An end capped, superficially porous particle with a pentafluorophenyl ligand	Phenomenex
Luna Omega C18*	100	1.6	An end capped, C18 alkyl ligand	Phenomenex
Luna Omega Polar C18*	100	1.6	An end capped, C18 alkyl ligand with polar modified particle surface	Phenomenex
Luna Omega PS C18*	100	1.6	An end capped, C18 alkyl ligand with a positive charge on the surface of the particle	Phenomenex
PLRP-S	100	3	A hydrophobic styrene /divinylbenzene polymeric particle with no bonded phase	Agilent
Polaris 3 Amide C18*	180	3	An end capped, monofunctional alkyl ligand with an embedded amide functionality	Agilent
Poroshell 120 Bonus-RP*	120	2.7	A triple end capped, superficially porous particle with a polar group embedded in the alkyl ligand	Agilent
Poroshell 120 PFP*	120	2.7	An end capped, superficially porous particle with a pentafluorophenyl ligand	Agilent
Poroshell 120 Phenyl Hexyl*	120	2.7	A double end capped, superficially porous particle with C6 alkyl chain and terminal phenyl functionality	Agilent
Poroshell 120 SB-AQ*	120	2.7	A non end capped, superficially porous particle with C18 alkyl ligand	Agilent
Poroshell HPH-C8	120	2.7	A double end capped, superficially porous particle with C8 alkyl ligand	Agilent
Poroshell HPH-C18*	120	2.7	A double end capped, superficially porous particle with C18 alkyl ligand	Agilent
Zorbax SB-C8*	80	1.8	A non end capped, C8 alkyl ligand with diisopropyl sterically protected siloxane bonds	Agilent
Zorbax SB-C18*	80	1.8	A non end capped, C18 alkyl ligand with diisobutyl sterically protected siloxane bonds	Agilent
Zorbax RRHD 300 SB-C18	300	1.8	A non end capped, C18 alkyl ligand with diisobutyl sterically protected siloxane bonds on wide pore material	Agilent

* Stationary phases compared using the Peptide RPC Column Characterisation Protocol, extended Tanaka protocol and Hydrophobic Subtraction Model

[†]Although 43 stationary phases are described in this table, only 38 could be fully characterised using the Peptide RPC Column Characterisation protocol. This was explained in Section 3.1.

Table 2

Peptide pairs used to measure delta values for column classification and rationale for their selection. The base sequences were described in *Section 2.1*. For further information regarding the selection of peptides, see References [9] and [10].

Change	Delta	Peptide Number	Net Charge		Peptide	Rationale	Average Δt_g (min)	Average Δt_g^* (-)
			FA	AF				
[Met10] → [Met(O)10]	$\Delta(8a,1)FA^*$	8a 1	1.2 1.2		[Met(O)10]-Bovine GLP-2 (1-15) [Met10]-Bovine GLP-2 (1-15)	Oxidation	-3.443	-0.288
[L-Asn11] → [L-Asp11]	$\Delta(9,1)FA$	9 1	1.1 1.2		[L-Asp11]-Bovine GLP-2 (1-15) [L-Asn11]-Bovine GLP-2 (1-15)	Increase in negative charge - deamidation	0.655	0.057
[L-Ser16] → [D-Ser16]	$\Delta(14,13)FA$	14 13	2.2 2.2		[D-Ser16]-Bovine GLP-2 (16-33) [L-Ser16]-Bovine GLP-2 (16-33)	Steric – racemisation	0.102	0.008
[Phe22] → [Gly22]	$\Delta(16,13)FA$	16 13	2.2 2.2		[Gly22]-Bovine GLP-2 (16-33) [Phe22]-Bovine GLP-2 (16-33)	Aromatic – removal of aromatic group	-4.609	-0.391
[Leu26] → [Lys26]	$\Delta(26,13)FA$	26 13	3.2 2.2		[Lys26]-Bovine GLP-2 (16-33) [Leu26]-Bovine GLP-2 (16-33)	Increase in positive charge	-6.664	-0.565
[Leu26,Ile27] → [Ile26,Leu27]	$\Delta(15,13)AF$	15 13		0 0	[Ile26,Leu27]-Bovine GLP-2 (16-33) [Leu26,Ile27]-Bovine GLP-2 (16-33)	Steric – switch in amino acid sequence	0.853	0.047
[Leu26] → [Tyr26]	$\Delta(24,13)AF$	24 13		0 0	[Tyr26]-Bovine GLP-2 (16-33) [Leu26]-Bovine GLP-2 (16-33)	Aromatic and phenolic – addition of phenolic group	-3.657	-0.172
[Leu26] → [Lys26]	$\Delta(26,13)AF$	26 13		1 0	[Lys26]-Bovine GLP-2 (16-33) [Leu26]-Bovine GLP-2 (16-33)	Increase in positive charge	-5.956	-0.284

*a corresponds to the first eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15)

NB The sign prior to the Δt_g^* in mins indicates the elution order e.g. [Leu26] → [Lys26] with a Δt_g of -8.213 means that [Lys26] elutes earlier than [Leu26]

Table 3

The regression coefficients between specific delta values and terms from the Hydrophobic Subtraction Model or extended Tanaka protocol.

Delta Value	Compared Against	Interaction Description with Respect to the Analyte	Regression Coefficient (R²)
$\Delta(9,1)$ FA	$\alpha_{(BSA/T)}$	Changes in negative charge	0.75 (0.25)*
$\Delta(9,1)$ FA	B	Changes in negative charge	0.55 (0.20)*
$\Delta(14,13)$ FA	S	Steric	0.32 (0.25)*
$\Delta(24,13)$ AF	$\alpha_{(C/P)}$	Hydrogen bonding	0.13 (0.10)*
$\Delta(26,13)$ FA	$\alpha_{(B/P)}$ pH 2.7	Changes in positive charge at low pH	0.55 (0.45)*
$\Delta(26,13)$ FA	C(2.8)	Changes in positive charge at low pH	0.73 (0.36)*
$\Delta(26,13)$ AF	$\alpha_{(B/P)}$ pH 7.6	Changes in positive charge at intermediate pH	0.15 (0.36)*
$\Delta(26,13)$ AF	C(7.0)	Changes in positive charge at intermediate pH	0.41 (0.41)*

* The most extreme column (Polaris Amide C18) was removed and in general this reduced the correlation between the different probes.